Modality
Cell Therapy
MOA
BCMA ADC
Target
PCSK9
Pathway
Angiogenesis
ADPKDIgANMelanoma
Development Pipeline
Preclinical
Mar 2020
→ Sep 2027
PreclinicalCurrent
NCT07646617
304 pts·Melanoma
2020-03→2027-09·Terminated
304 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-09-071.4y awayInterim· Melanoma
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Termina…
Catalysts
Interim
2027-09-07 · 1.4y away
Melanoma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07646617 | Preclinical | Melanoma | Terminated | 304 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanusertib | AbbVie | Approved | PCSK9 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα |